Open house Arzneimittelrabattverträge Formoterol und Aclidiniumbromid, ATC R03AL05
Original notice title
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Formoterol und Aclidiniumbromid, ATC R03AL05
Opportunity Score
Why this score?
Opportunity
50 / 100
Complexity
20 / 100
Risk factors
No estimated value or guaranteed volume is provided. The commercial benefit is entirely dependent on the number of pres...
The open-house agreement automatically ceases if a formal discount contract for the same active substance is concluded...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Overview
Moderate opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Apr 2027
- Conclusion of non-exclusive discount agreements for pharmaceutical products with active substances Formoterol and Aclidiniumbromid (ATC R03AL05)
- Open-house model: no selection, all eligible companies can participate
Show full summary
This is an open-house model (not a formal tender) by AOK Bayern for non-exclusive discount agreements on pharmaceutical products with active substances Formoterol and Aclidiniumbromid (ATC R03AL05). All interested pharmaceutical companies that meet the eligibility criteria can enter into identical, non-negotiable agreements. The earliest contract start is 01.05.2025, and all contracts end on 30.04.2027. Contracts can be concluded at any time until 05.03.2027. The notice is published for transparency but is not subject to procurement law. No estimated value is provided.
Risks
No estimated value or guaranteed volume is provided. The commercial benefit is entirely dependent on the number of pres...
The open-house agreement automatically ceases if a formal discount contract for the same active substance is concluded...
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Eligibility
- Only pharmaceutical companies are eligible
Administrative
- Must submit a signed self-declaration of reliability
- Must submit the signed contract and the completed annex 'Festlegung der vertragsgegenständlichen Arzneimittel'
Requirements may be incomplete.
Buyer
Location
München, DEU
Website
Buyer profile
Identifier
DE811695320
Activity
Health
Lots (1)
LOT-0001
Open house Arzneimittelrabattverträge Formoterol und Aclidiniumbromid, ATC R03AL05
Non-exclusive discount agreements for pharmaceutical products containing Formoterol and Aclidiniumbromid (ATC R03AL05). All interested pharmaceutical companies can join under identical terms.
Location
Duration
Category
Deadline
Award details
Siehe kurze Beschreibung ACHTUNG: Die Vertragsunterlagen sind zwingend über den Kommunikationsbereich im Vergabeportal www.dtvp.de einzureichen und keinesfalls über den Angebotsbereich!
Show original TED data
Original TED description
Siehe kurze Beschreibung ACHTUNG: Die Vertragsunterlagen sind zwingend über den Kommunikationsbereich im Vergabeportal www.dtvp.de einzureichen und keinesfalls über den Angebotsbereich!
Procurement Details
- Publication date
- 18 Mar 2025
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 178186-2025
Documents (2)
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Denmark – Pharmaceutical products – Amgros 2027 1.1170.a
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
50 / 100
Complexity
20 / 100
Risk factors
No estimated value or guaranteed volume is provided. The commercial benefit is entirely dependent on the number of pres...
The open-house agreement automatically ceases if a formal discount contract for the same active substance is concluded...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications